JPH0480026B2 - - Google Patents
Info
- Publication number
- JPH0480026B2 JPH0480026B2 JP61234248A JP23424886A JPH0480026B2 JP H0480026 B2 JPH0480026 B2 JP H0480026B2 JP 61234248 A JP61234248 A JP 61234248A JP 23424886 A JP23424886 A JP 23424886A JP H0480026 B2 JPH0480026 B2 JP H0480026B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- general formula
- inorganic acid
- acceptable organic
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 claims abstract description 5
- BBCFOMHGZMWTHH-UHFFFAOYSA-N 2-piperidin-1-ylethyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OCCN1CCCCC1 BBCFOMHGZMWTHH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- -1 inorganic acid salts Chemical class 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- YPMPTULBFPFSEQ-PLNGDYQASA-N ethyl (z)-3-aminobut-2-enoate Chemical compound CCOC(=O)\C=C(\C)N YPMPTULBFPFSEQ-PLNGDYQASA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 230000008602 contraction Effects 0.000 description 13
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229960001783 nicardipine Drugs 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 6
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 229960001597 nifedipine Drugs 0.000 description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 5
- 229960000715 nimodipine Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960005425 nitrendipine Drugs 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- UKVYVZLTGQVOPX-IHWYPQMZSA-N (z)-3-aminobut-2-enoic acid Chemical compound C\C(N)=C\C(O)=O UKVYVZLTGQVOPX-IHWYPQMZSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003184 effect on constriction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical group CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- GFUCMNMXYOVTDJ-UHFFFAOYSA-N 2,4-diamino-6-butan-2-ylphenol Chemical compound CCC(C)C1=CC(N)=CC(N)=C1O GFUCMNMXYOVTDJ-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- BJCDLTBTUIMEOQ-UHFFFAOYSA-N 2-piperidin-1-ylethyl acetate Chemical compound CC(=O)OCCN1CCCCC1 BJCDLTBTUIMEOQ-UHFFFAOYSA-N 0.000 description 1
- GRDAOFITFJWKFJ-UHFFFAOYSA-N 3-o-ethyl 5-o-(2-piperidin-1-ylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCCCC2)C1C1=CC=CC([N+]([O-])=O)=C1 GRDAOFITFJWKFJ-UHFFFAOYSA-N 0.000 description 1
- YXOZFHCCJWVVQP-UHFFFAOYSA-N 4-ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1-(2-piperidin-1-ylethyl)pyridine-3,5-dicarboxylic acid Chemical compound CC1=C(C(O)=O)C(CC)(C=2C=C(C=CC=2)[N+]([O-])=O)C(C(O)=O)=C(C)N1CCN1CCCCC1 YXOZFHCCJWVVQP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
- 102100035915 D site-binding protein Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 101000873522 Homo sapiens D site-binding protein Proteins 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101000898291 Nicotiana tabacum Catalase isozyme 1 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 101000979255 Sus scrofa Neurolysin, mitochondrial Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- DDPMGIMJSRUULN-UHFFFAOYSA-N buphedrone Chemical compound CCC(NC)C(=O)C1=CC=CC=C1 DDPMGIMJSRUULN-UHFFFAOYSA-N 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
æ¬çºæã¯äžè¬åŒ
ã®ãžãããããªãžã³èªå°äœåã³ïŒãããã®ææ©å
ã¯ç¡æ©é žãšã®è¬åŠçã«å®¹èªã§ããçµæç©ããã®è£œ
é æ¹æ³åã³ããããå«ãè¬åŠççµæç©ã«é¢ããã ååç©åã¯ãšãã«âïŒÎ²âãããªãžããšãã«ïŒ
âïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâãããããšãã«ïŒ
âïŒïŒïŒâãžãããããªãžã³âïŒïŒïŒâãžã«ã«ã
ãã·ã¬ãŒãïŒä»¥äžç°¡ç¥ããŠãYS201ã®ç¥ç§°ã以ã€
ãŠåŒã¶ïŒã¯è©Šéšç®¡å åã³çäœå ã§ã«ã«ã·ãŠã æ®æ
äœçšãæããããæ ã人éã®æ²»çã«æå¹ã§ããã ã«ã«ã·ãŠã æ®æäœçšãæã€ãžãããããªãžã³å
åç©ã¯æ¢ã«èšèŒãããŠãããæè¡å§å€ãæâå±æ
貧è¡å€åã³æäžæŽèå€ãšããŠæ²»çã«çšããããŠã
ããæ®ã«ãããšãžãã³ãšåŒã°ããååç©
ïŒUS3485847åã³US3644627ïŒããã«ã«ãžãã³ïŒç¹
éæ74â109384ïŒããã¢ãžãã³åã³ããã¬ã³ãžã
ã³ïŒDE2117571åã³2117573ïŒã¯åºãç¥ãããäž
ã€äœ¿çšãããŠããã ãããååç©ã¯å ±éããŠãïŒïŒïŒâãžãããâ
ïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâãããããšãã«ïŒâ
ïŒïŒïŒâããªãžã³ãžã«ã«ããã·ãŒã«æ§é ãæãã
ïŒäœåã³ïŒäœã®ã«ã«ããã·åºã®ãšã¹ãã«ã ããç°
ãªã€ãŠããããããšãžãã³ã¯ãžã¡ãã«ãšã¹ãã«ã§
ãããããã¢ãžãã³ãããã¬ã³ãžãã³åã³ãã«ã«
ãžãã³ã¯é察称ãšã¹ãã«ã§ãããå³ã¡ããã¢ãžã
ã³ã¯ã€ãœãããã«ïŒâã¡ããã·ãšãã«ãšã¹ãã«ã
ããã¬ãžãã³ã¯ã¡ãã«ãšãã«ãšã¹ãã«ããããŠã
ã«ã«ãžãã³ã¯ã¡ãã«ïŒïŒ®âãã³ãã«ââã¡ãã«
ã¢ããïŒãšãã«ãšã¹ãã«ã§ããããã«ã«ãžãã³ã
ãã¯ã¢ãããšã¹ãã«åºãååšããŠããç¹ã§ç¹åŸŽã
ããã ãšã¹ãã«åºãçžç°ããŠããçµæãšããŠçç©åŠç
ãªç¹æ§ãšç¶æ ã®ç°ãªã€ãååç©ãåŸãããããã®
çµæãåçš®ã®ïŒïŒïŒâãžãããããªãžã³âïŒïŒïŒ
âãžã«ã«ãã³é žãšã¹ãã«ãåæããããã«å€ãã®
ç 究åªåããªãããã ãžãããããªãžã³ç³»èªå°äœã®ïŒã€ã®ãšã¹ãã«æ®
åºã®äžã€ã«å¡©åºæ§æ®åºãå°å ¥ããããšã¯ãåããŠ
ãã€ãšã«ã«ããDE2218644ïŒGB1363623åã³
US3905970ã«å¯Ÿå¿ïŒã«èª¬æãããŠãããæ¬çºæã®
察象ã§ããååç©ãYS201ã¯äžèšç¹èš±ã«ç¹èš±è«æ±
ãããŠããäžè¬åŒã®å®çŸ©ã®äžã«å«ãŸããŠãããã
ãããªãžã³åºããšã¹ãã«æ®åºäžã«æã€ååç©ã¯å®
éã«ã¯å šã補é ãããŠããªãããããŠã¢ã«ããªã³
åã¯ïŒ®âã¡ãã«ããã©ãžã³åºãæã€å€ãã®ååç©
ãåæããããã ç¹éæ74â109384ãã¢ãããšã¹ãã«ïŒãã«ã«ãž
ãã³ïŒã«é¢ããæã«ç°ç¶ã¢ãããšã¹ãã«åºïŒÎ²â
ãããžããšãã«ïŒã®ïŒäŸããå ¬éããŠããªãã ãšããã§äžè¿°ããæ§ã«ãçŸã«èšåºçã«äœ¿çšãã
ãŠãã奜ãŸããååç©ã¯éç°ç¶ãšã¹ãã«ãå³ã¡ã
ã«ã«ãžãã³ã§ããã ãžãããããªãžã³ãžã«ã«ãã³é žã®å¡©åºæ§ãšã¹ã
ã«ã®å¥ã®äŸã¯EPââ97821ã«å ¬éãããŠããã
ããã§ã¯ïŒ®â眮æããã©ãžãã¢ã«ãã«æ®åºãç¹èš±
è«æ±ãããŠãããå¡©åºæ§ãšã¹ãã«ãç¹èš±è«æ±ããŠ
ããEPââ63365ã§ã¯ïŒ®â眮æãããªãžã³ç°ã
å«ã¿ãæ¬çºæã®ååç©ãšã¯å šãç°ãªãæ§é ã®ãã®
ã§ããã é©ãã¹ãããšã«ã¯ãYS201ãåªããæ§è³ªãšåŸæ¥
æè¡ã®ååç©ãšã¯å šãç°ãªãè¬åŠçæ§ç¶ãšãæã
ãããšãå€ã€ãã æ®ã«ååç©ã¯ã«ã«ã·ãŠã æ®æå€ãšããŠãŸãã«
ã«ã·ãŠã âãªãŒããŒããŒããããã«ãŒãšããŠã®ã
ã®ãã®ã®æŽ»æ§ã«ããããŸãåŒçšååç©ãããã»ã©
æå¹ã§ãªãæ§ãªå Žåã«ãããŠããã®è¬å€ã®æ²»çäž
ã®å¹åã®åºç€ã«ãªã€ãŠããç°ãªãäœçšæ©äœã«ãã€
ãŠæ²»çäžã®é²æ©æ§ãæããŠããããã®ããšã¯æã
éžæçã§ãã倧ããªçµæãæãæ¯æ§ãäœãæ°ãã
ååç©ã®äœ¿çšã®å¿ èŠæ§ãæ£åœåããåŠãå¿èè¡ç®¡
ç çã®åéã«ãããŠç¹ã«éèŠã§ããã ååç©YS201ãæ§é çã«é¢é£ã®ãã極ããŠè¯ã
ç¥ãããïŒã€ã®ãžãããããªãžã³ååç©ã§ããã
çŸã«äººéã®èšºçã«çšããããŠãããããšãžãã³ã
ãã¢ãžãã³ãããã¬ã³ãžãã³åã³ãã«ã«ãžãã³ãš
è¬çåŠçã«æ¯èŒããããããŠæåŸã®ãã®ã¯æãå¹
åã®ããã¢ãããšã¹ãã«ã§ããå®éèšåºå®åã«çš
ããããŠããå¯äžã®ãã®ã§ãããYS201ãïŒã€ã®
å¥ã®å ¬ç¥ã®ã«ã«ã·ãŠã æ®æå€ãã©ããã«åã³ãžã«
ãã¢ãŒã ãšãæ¯èŒããã æ¥æ§æ¯æ§ ã©ããåã³ããŠã¹ã®éåã³éã«åæ§ã«è¡ç®¡å ã«
æäžããYS201ã®æ¥æ§æ¯æ§ã¯äžèšã®ãšããã§ã
ãïŒ ã©ãã ããŠã¹ LD50 12.53mgïŒKg 12.29mgïŒKg äž é 11.65mgïŒKg 11.46mgïŒKg äž é 13.47mgïŒKg 13.18mgïŒKg ã©ããåã³ããŠã¹ã®éåã³éã«åæ§ã«çµå£çã«
æäžããYS201ã®æ¥æ§æ¯æ§ã¯äžèšã®ãšããã§ã
ãïŒ ã©ãã ããŠã¹ LD50 402.12mgïŒKg 282.77mgïŒKg äž é 362.58mgïŒKg 257.55mgïŒKg äž é 458.62mgïŒKg 310.46mgïŒKg è¬åŠçæ§è³ª ïŒ è©Šéšç®¡äžã§ã®å¿èè管ã®åçž®å¿çã®æå¶ ä»¥äžã«èª¬æãããã¹ãã®çµæãè¡šïŒã«å ±åã
ãã (1.1) ã©ããèžéšå€§åè ã©ããèžéšå€§åèãã倧åèã¹ããªãã
ïŒïŒmmå¹ ïŒãåãåãã38âã§O2ïŒCO2ïŒ95ïŒ
ïŒïŒãããã«ããŠããã¯ã¬ãŒãã¹ãŒãã³ã»ã©
ã€ã溶液äžã«å ¥ããïŒïœã®ç·åŒµãäžããã30
åã®å®å®æéã®åŸã«ã«ã«ã·ãŠã ãå«ãŸãªãåª
äœïŒNa EDTA0.1ïœM.λâïŒïŒäžKClïŒ118ïœ
ïŒïŒåã¯ãã«ã¢ãã¬ããªã³ïŒ10-5M.λâïŒïŒ
ãå ããããåã¯ã«ã«ã·ãŠã ïŒCaCl21.25ïœ
ïŒïŒÎ»âïŒïŒã®åæå ¥åŸããã«ã¢ãã¬ããªã³
ïŒïŒ10-5M.λâïŒïŒãå ããããšã«ãã€ãŠåçž®
ãèµ·ãããã (1.2) SHR倧åè èªç¶é«è¡å§ã©ããïŒSHRïŒããããšãã«
ãšããªã³âïŒPEã1ÎŒMïŒå瞮倧åèè¡ç®¡ã«ã
ããæ¡åŒµäœçšã«ã€ãããããšãžãã³ãšã®æ¯èŒ
ãã¹ããè¡ã€ããååç©ãPEâåçž®è¡ç®¡ã«
挞å¢çãªé«æ¿åºŠã§å ããã (1.3) SHR倧åèâååŠçç 究 SHR倧åèãPEïŒ1ÎŒMïŒãåã¯é«ã«ãªãŠ
ã ïŒK+ã80ïœïŒïŒã§åŠçããåŸãããåçž®
ã15åéæŸçœ®ãããæŽæ»ãïŒæé平衡ç¶æ ã«
ããã®ã¡ãçµç¹ãYS201ãåã¯ãããšãžãã³
ã®ã·ã³ã°ã«æ¿åºŠã§äºãåŠçããã30åã®å¹³è¡¡
åæéã®åŸãçµç¹ãåã³PEåã¯K+ã§åŠç
ããåŸãããåçž®ãæåã®åçž®ãšæ¯èŒããã
åçž®å¹æããããã¢ãŽãã¹ãïŒPEãŸãã¯
K+ïŒãå ããåŸã15ååŸã«æž¬å®ããã
ã¯ç¡æ©é žãšã®è¬åŠçã«å®¹èªã§ããçµæç©ããã®è£œ
é æ¹æ³åã³ããããå«ãè¬åŠççµæç©ã«é¢ããã ååç©åã¯ãšãã«âïŒÎ²âãããªãžããšãã«ïŒ
âïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâãããããšãã«ïŒ
âïŒïŒïŒâãžãããããªãžã³âïŒïŒïŒâãžã«ã«ã
ãã·ã¬ãŒãïŒä»¥äžç°¡ç¥ããŠãYS201ã®ç¥ç§°ã以ã€
ãŠåŒã¶ïŒã¯è©Šéšç®¡å åã³çäœå ã§ã«ã«ã·ãŠã æ®æ
äœçšãæããããæ ã人éã®æ²»çã«æå¹ã§ããã ã«ã«ã·ãŠã æ®æäœçšãæã€ãžãããããªãžã³å
åç©ã¯æ¢ã«èšèŒãããŠãããæè¡å§å€ãæâå±æ
貧è¡å€åã³æäžæŽèå€ãšããŠæ²»çã«çšããããŠã
ããæ®ã«ãããšãžãã³ãšåŒã°ããååç©
ïŒUS3485847åã³US3644627ïŒããã«ã«ãžãã³ïŒç¹
éæ74â109384ïŒããã¢ãžãã³åã³ããã¬ã³ãžã
ã³ïŒDE2117571åã³2117573ïŒã¯åºãç¥ãããäž
ã€äœ¿çšãããŠããã ãããååç©ã¯å ±éããŠãïŒïŒïŒâãžãããâ
ïŒïŒïŒâãžã¡ãã«âïŒâïŒïŒâãããããšãã«ïŒâ
ïŒïŒïŒâããªãžã³ãžã«ã«ããã·ãŒã«æ§é ãæãã
ïŒäœåã³ïŒäœã®ã«ã«ããã·åºã®ãšã¹ãã«ã ããç°
ãªã€ãŠããããããšãžãã³ã¯ãžã¡ãã«ãšã¹ãã«ã§
ãããããã¢ãžãã³ãããã¬ã³ãžãã³åã³ãã«ã«
ãžãã³ã¯é察称ãšã¹ãã«ã§ãããå³ã¡ããã¢ãžã
ã³ã¯ã€ãœãããã«ïŒâã¡ããã·ãšãã«ãšã¹ãã«ã
ããã¬ãžãã³ã¯ã¡ãã«ãšãã«ãšã¹ãã«ããããŠã
ã«ã«ãžãã³ã¯ã¡ãã«ïŒïŒ®âãã³ãã«ââã¡ãã«
ã¢ããïŒãšãã«ãšã¹ãã«ã§ããããã«ã«ãžãã³ã
ãã¯ã¢ãããšã¹ãã«åºãååšããŠããç¹ã§ç¹åŸŽã
ããã ãšã¹ãã«åºãçžç°ããŠããçµæãšããŠçç©åŠç
ãªç¹æ§ãšç¶æ ã®ç°ãªã€ãååç©ãåŸãããããã®
çµæãåçš®ã®ïŒïŒïŒâãžãããããªãžã³âïŒïŒïŒ
âãžã«ã«ãã³é žãšã¹ãã«ãåæããããã«å€ãã®
ç 究åªåããªãããã ãžãããããªãžã³ç³»èªå°äœã®ïŒã€ã®ãšã¹ãã«æ®
åºã®äžã€ã«å¡©åºæ§æ®åºãå°å ¥ããããšã¯ãåããŠ
ãã€ãšã«ã«ããDE2218644ïŒGB1363623åã³
US3905970ã«å¯Ÿå¿ïŒã«èª¬æãããŠãããæ¬çºæã®
察象ã§ããååç©ãYS201ã¯äžèšç¹èš±ã«ç¹èš±è«æ±
ãããŠããäžè¬åŒã®å®çŸ©ã®äžã«å«ãŸããŠãããã
ãããªãžã³åºããšã¹ãã«æ®åºäžã«æã€ååç©ã¯å®
éã«ã¯å šã補é ãããŠããªãããããŠã¢ã«ããªã³
åã¯ïŒ®âã¡ãã«ããã©ãžã³åºãæã€å€ãã®ååç©
ãåæããããã ç¹éæ74â109384ãã¢ãããšã¹ãã«ïŒãã«ã«ãž
ãã³ïŒã«é¢ããæã«ç°ç¶ã¢ãããšã¹ãã«åºïŒÎ²â
ãããžããšãã«ïŒã®ïŒäŸããå ¬éããŠããªãã ãšããã§äžè¿°ããæ§ã«ãçŸã«èšåºçã«äœ¿çšãã
ãŠãã奜ãŸããååç©ã¯éç°ç¶ãšã¹ãã«ãå³ã¡ã
ã«ã«ãžãã³ã§ããã ãžãããããªãžã³ãžã«ã«ãã³é žã®å¡©åºæ§ãšã¹ã
ã«ã®å¥ã®äŸã¯EPââ97821ã«å ¬éãããŠããã
ããã§ã¯ïŒ®â眮æããã©ãžãã¢ã«ãã«æ®åºãç¹èš±
è«æ±ãããŠãããå¡©åºæ§ãšã¹ãã«ãç¹èš±è«æ±ããŠ
ããEPââ63365ã§ã¯ïŒ®â眮æãããªãžã³ç°ã
å«ã¿ãæ¬çºæã®ååç©ãšã¯å šãç°ãªãæ§é ã®ãã®
ã§ããã é©ãã¹ãããšã«ã¯ãYS201ãåªããæ§è³ªãšåŸæ¥
æè¡ã®ååç©ãšã¯å šãç°ãªãè¬åŠçæ§ç¶ãšãæã
ãããšãå€ã€ãã æ®ã«ååç©ã¯ã«ã«ã·ãŠã æ®æå€ãšããŠãŸãã«
ã«ã·ãŠã âãªãŒããŒããŒããããã«ãŒãšããŠã®ã
ã®ãã®ã®æŽ»æ§ã«ããããŸãåŒçšååç©ãããã»ã©
æå¹ã§ãªãæ§ãªå Žåã«ãããŠããã®è¬å€ã®æ²»çäž
ã®å¹åã®åºç€ã«ãªã€ãŠããç°ãªãäœçšæ©äœã«ãã€
ãŠæ²»çäžã®é²æ©æ§ãæããŠããããã®ããšã¯æã
éžæçã§ãã倧ããªçµæãæãæ¯æ§ãäœãæ°ãã
ååç©ã®äœ¿çšã®å¿ èŠæ§ãæ£åœåããåŠãå¿èè¡ç®¡
ç çã®åéã«ãããŠç¹ã«éèŠã§ããã ååç©YS201ãæ§é çã«é¢é£ã®ãã極ããŠè¯ã
ç¥ãããïŒã€ã®ãžãããããªãžã³ååç©ã§ããã
çŸã«äººéã®èšºçã«çšããããŠãããããšãžãã³ã
ãã¢ãžãã³ãããã¬ã³ãžãã³åã³ãã«ã«ãžãã³ãš
è¬çåŠçã«æ¯èŒããããããŠæåŸã®ãã®ã¯æãå¹
åã®ããã¢ãããšã¹ãã«ã§ããå®éèšåºå®åã«çš
ããããŠããå¯äžã®ãã®ã§ãããYS201ãïŒã€ã®
å¥ã®å ¬ç¥ã®ã«ã«ã·ãŠã æ®æå€ãã©ããã«åã³ãžã«
ãã¢ãŒã ãšãæ¯èŒããã æ¥æ§æ¯æ§ ã©ããåã³ããŠã¹ã®éåã³éã«åæ§ã«è¡ç®¡å ã«
æäžããYS201ã®æ¥æ§æ¯æ§ã¯äžèšã®ãšããã§ã
ãïŒ ã©ãã ããŠã¹ LD50 12.53mgïŒKg 12.29mgïŒKg äž é 11.65mgïŒKg 11.46mgïŒKg äž é 13.47mgïŒKg 13.18mgïŒKg ã©ããåã³ããŠã¹ã®éåã³éã«åæ§ã«çµå£çã«
æäžããYS201ã®æ¥æ§æ¯æ§ã¯äžèšã®ãšããã§ã
ãïŒ ã©ãã ããŠã¹ LD50 402.12mgïŒKg 282.77mgïŒKg äž é 362.58mgïŒKg 257.55mgïŒKg äž é 458.62mgïŒKg 310.46mgïŒKg è¬åŠçæ§è³ª ïŒ è©Šéšç®¡äžã§ã®å¿èè管ã®åçž®å¿çã®æå¶ ä»¥äžã«èª¬æãããã¹ãã®çµæãè¡šïŒã«å ±åã
ãã (1.1) ã©ããèžéšå€§åè ã©ããèžéšå€§åèãã倧åèã¹ããªãã
ïŒïŒmmå¹ ïŒãåãåãã38âã§O2ïŒCO2ïŒ95ïŒ
ïŒïŒãããã«ããŠããã¯ã¬ãŒãã¹ãŒãã³ã»ã©
ã€ã溶液äžã«å ¥ããïŒïœã®ç·åŒµãäžããã30
åã®å®å®æéã®åŸã«ã«ã«ã·ãŠã ãå«ãŸãªãåª
äœïŒNa EDTA0.1ïœM.λâïŒïŒäžKClïŒ118ïœ
ïŒïŒåã¯ãã«ã¢ãã¬ããªã³ïŒ10-5M.λâïŒïŒ
ãå ããããåã¯ã«ã«ã·ãŠã ïŒCaCl21.25ïœ
ïŒïŒÎ»âïŒïŒã®åæå ¥åŸããã«ã¢ãã¬ããªã³
ïŒïŒ10-5M.λâïŒïŒãå ããããšã«ãã€ãŠåçž®
ãèµ·ãããã (1.2) SHR倧åè èªç¶é«è¡å§ã©ããïŒSHRïŒããããšãã«
ãšããªã³âïŒPEã1ÎŒMïŒå瞮倧åèè¡ç®¡ã«ã
ããæ¡åŒµäœçšã«ã€ãããããšãžãã³ãšã®æ¯èŒ
ãã¹ããè¡ã€ããååç©ãPEâåçž®è¡ç®¡ã«
挞å¢çãªé«æ¿åºŠã§å ããã (1.3) SHR倧åèâååŠçç 究 SHR倧åèãPEïŒ1ÎŒMïŒãåã¯é«ã«ãªãŠ
ã ïŒK+ã80ïœïŒïŒã§åŠçããåŸãããåçž®
ã15åéæŸçœ®ãããæŽæ»ãïŒæé平衡ç¶æ ã«
ããã®ã¡ãçµç¹ãYS201ãåã¯ãããšãžãã³
ã®ã·ã³ã°ã«æ¿åºŠã§äºãåŠçããã30åã®å¹³è¡¡
åæéã®åŸãçµç¹ãåã³PEåã¯K+ã§åŠç
ããåŸãããåçž®ãæåã®åçž®ãšæ¯èŒããã
åçž®å¹æããããã¢ãŽãã¹ãïŒPEãŸãã¯
K+ïŒãå ããåŸã15ååŸã«æž¬å®ããã
ãè¡šã
äžã«å ±åããçµæãããYS201ã¯æ¯èŒååç©ã
ããK+ãCa++ãšãã«ã¢ãããªã³ãšã§èªå°ããå
çž®ã«ã€ãå¯æã掻æ§ã倧ããããäžæ¹ããã¬ã³ãž
ãã³ã¯Ca++ãæããªãåªäœäžããã«ã¢ãã¬ããª
ã³ã§èªå°ããåçž®ã«å¯ŸããYS201ããã幟å掻æ§
ã§ããããšãæçœã§ããã SHR倧åèãœã«ããã¯ïŒsorticïŒã¹ããªããã«
ãããŠãYS201ãšãããšãžãã³ãšã¯K+âèªå°å
çž®ã®æ¥µããŠé«ãææ¢å€ã§ããã èªç¶é«è¡å§ã©ããïŒSHRïŒã§è¡ãããçäœå
ç 究ã«ãããŠãYS201ã¯ãæ®ã«åäºæè žçµç±ã§æ
äžããå ŽåãçšéäŸåã®å€§ããªæŽ»æ§ãæããŠãã
ããšãæããã«ãªã€ããè èé«å§ã©ããã«ãã
ãŠãYS201ããäžæ¥ïŒås.c.æäžã10æ¥è¡ããšã
å®å®è¡å§ãèããäœäžãããäžå®ãšåªåã«ããåŒ
èµ·ãããè¡å§å¢å€§ãäœäžãããã ïŒã±æã©ããåã³ïŒã±æçµéSHRâSPã§ã®
YS201ã®æ¯èŒå¹æ ç·åŒµæ£åžžã©ããã«15mgïŒKgã§åäºæè žçµç±ã§
YS201ãæäžãããå¿æ¡åŒµæè¡å§ïŒDBPïŒã¯
3.1KPAã«ãããæäžåŸïŒåéã§èããæžå°ãã
ãã®æžå°ã¯60ååŸã«ããªãé¡èã§ãã€ããå¿èå
çž®å§ãèããæžå°ããïŒè¡šïŒïŒã ïŒã±æçµéåŸSHRâSPã§ã¯ãYS201ã¯SBPã«
ããããããDBPã«ãããŠãããèããæžå°ã
çãããã®å¹æã¯ïŒæéæç¶ããŠããïŒè¡š2aïŒ
ããK+ãCa++ãšãã«ã¢ãããªã³ãšã§èªå°ããå
çž®ã«ã€ãå¯æã掻æ§ã倧ããããäžæ¹ããã¬ã³ãž
ãã³ã¯Ca++ãæããªãåªäœäžããã«ã¢ãã¬ããª
ã³ã§èªå°ããåçž®ã«å¯ŸããYS201ããã幟å掻æ§
ã§ããããšãæçœã§ããã SHR倧åèãœã«ããã¯ïŒsorticïŒã¹ããªããã«
ãããŠãYS201ãšãããšãžãã³ãšã¯K+âèªå°å
çž®ã®æ¥µããŠé«ãææ¢å€ã§ããã èªç¶é«è¡å§ã©ããïŒSHRïŒã§è¡ãããçäœå
ç 究ã«ãããŠãYS201ã¯ãæ®ã«åäºæè žçµç±ã§æ
äžããå ŽåãçšéäŸåã®å€§ããªæŽ»æ§ãæããŠãã
ããšãæããã«ãªã€ããè èé«å§ã©ããã«ãã
ãŠãYS201ããäžæ¥ïŒås.c.æäžã10æ¥è¡ããšã
å®å®è¡å§ãèããäœäžãããäžå®ãšåªåã«ããåŒ
èµ·ãããè¡å§å¢å€§ãäœäžãããã ïŒã±æã©ããåã³ïŒã±æçµéSHRâSPã§ã®
YS201ã®æ¯èŒå¹æ ç·åŒµæ£åžžã©ããã«15mgïŒKgã§åäºæè žçµç±ã§
YS201ãæäžãããå¿æ¡åŒµæè¡å§ïŒDBPïŒã¯
3.1KPAã«ãããæäžåŸïŒåéã§èããæžå°ãã
ãã®æžå°ã¯60ååŸã«ããªãé¡èã§ãã€ããå¿èå
çž®å§ãèããæžå°ããïŒè¡šïŒïŒã ïŒã±æçµéåŸSHRâSPã§ã¯ãYS201ã¯SBPã«
ããããããDBPã«ãããŠãããèããæžå°ã
çãããã®å¹æã¯ïŒæéæç¶ããŠããïŒè¡š2aïŒ
ãè¡šã
ãè¡šã
ïŒã±æçµéã®SHRâSPã§ã¯YS201ã¯SBPã«ãã
ããèããDBPã§ã®æžå°ãçãããå¹æã¯ïŒæ
éã§çµäºããã
ããèããDBPã§ã®æžå°ãçãããå¹æã¯ïŒæ
éã§çµäºããã
ãè¡šã
æ¥æ§çžåã¯å埪ç°æéã«ãããå ç¶åèçµçŽ®åŸ
ã®å¿å®€äžæŽè ã¹ãã©ã°ãŒããŠã¬ã€ã©ããã«ã¯ã©ãŒã¯å€ã®æ¹æ³
ïŒJ.Pharmacol.MethodsïŒã357â368ïŒ1980ïŒã«
ãããå·Šå ç¶åèã®çµçŽ®ãè¡ãªããè¬å€ããã®çµ
玮åã30åã«å ¥ããŠãŒãããæäžãããé£ç¶å¿é»
å³èšé²ã«ãããšã¯ãããã¯ããŒãïŒEBïŒãå¿å®€äž
æŽèïŒVTïŒãå¿å®€çŽ°åïŒVFïŒãçµçŽ®åŸ30åéã
èšé²ããã åç©ã®ä»ã®ã°ã«ãŒãã§ã¯ãïŒååŸã«çµçŽ®ãåã
å»ã€ãããã®å ŽåãäžæŽèã®å¢å€§ãšæ»äº¡çã®å¢å€§
ãæ¥ãããã次èšè¡šïŒãšïŒãšã«å ±åããããŒã¿
ã¯ãYS201ãäžæŽèãåçã«æžå°ããããããšã
瀺ããŠãããYS201ã®æ²»çå¹æã¯å埪ç°åŸã«ãã
ãäžæŽèã®é»æ¢ã«ãããŠæ¯èŒè¬å€ã®ãããããç¹
ã«é¥ã«å€§ããã®ã§ããã
ã®å¿å®€äžæŽè ã¹ãã©ã°ãŒããŠã¬ã€ã©ããã«ã¯ã©ãŒã¯å€ã®æ¹æ³
ïŒJ.Pharmacol.MethodsïŒã357â368ïŒ1980ïŒã«
ãããå·Šå ç¶åèã®çµçŽ®ãè¡ãªããè¬å€ããã®çµ
玮åã30åã«å ¥ããŠãŒãããæäžãããé£ç¶å¿é»
å³èšé²ã«ãããšã¯ãããã¯ããŒãïŒEBïŒãå¿å®€äž
æŽèïŒVTïŒãå¿å®€çŽ°åïŒVFïŒãçµçŽ®åŸ30åéã
èšé²ããã åç©ã®ä»ã®ã°ã«ãŒãã§ã¯ãïŒååŸã«çµçŽ®ãåã
å»ã€ãããã®å ŽåãäžæŽèã®å¢å€§ãšæ»äº¡çã®å¢å€§
ãæ¥ãããã次èšè¡šïŒãšïŒãšã«å ±åããããŒã¿
ã¯ãYS201ãäžæŽèãåçã«æžå°ããããããšã
瀺ããŠãããYS201ã®æ²»çå¹æã¯å埪ç°åŸã«ãã
ãäžæŽèã®é»æ¢ã«ãããŠæ¯èŒè¬å€ã®ãããããç¹
ã«é¥ã«å€§ããã®ã§ããã
ãè¡šã
ããé£ç¶æ§ãä¿®æ£ããã
ãè¡šã
äžèšããŒã¿ãããã©ã®çšéãæäžããŠãã
YS201ã¯EBsåã³VTã«åºã¥ãã€ã³ããã¯ã¹ãã
ã»ãŒïŒåæžå°ãããããVFâãšããœãŒã
ïŒepisodesïŒæéãšå¹²æžããªãããšãã«ãæãã
ããVFã瀺ãã©ããã®ããŒã»ã³ããŒãžã¯1.5mgïŒ
Kg-1ã§èããæžå°ããŠããããšãæããã«ãªã€
ããå埪ç°ã«ãã€ãŠã¯ã7.5åã³15mgïŒKg-1ã®
YS201ã¯äœãããæ©æECGé害ãèããäœäžã
ããã¯ã©ã³ãã¹ïŒclampsïŒã解é€ãããèæ ®ã«
å ¥ãããã©ã¡ãŒã¿ã¯ãã¹ãŠæžå°ãæ»äº¡ã¯15mgïŒKg
-1ïŒïŒ°ïŒ0.02ïŒã§å®å šã«æå§ãããã ã©ããã§ã®äžæçãªè³ãªãªãŽãšãã¢
ïŒoligoemiaïŒ ãCirculation et Metabolis du CerveauïŒã
63â79ããJohn Libbey Eurotext Publ.ïŒ1983ïŒ
ã«ãã«ããšã€ãã¯ã¹ã«ãã説æãããæ¹æ³ãã60
åã®éäž¡åŽé žåèçµçŽ®ããçŽ10é±ã®éã¹ãã©ã°â
ããŠã¬ã€ã©ãããçšããŠè¡ãªã€ããåç©ããçµçŽ®
åŸïŒæéåŸã«éå§ããã¹ã«ã©ãŒçšéã§ãïŒæ¥éã
ïŒæ¥ïŒåãè©Šéšè¬å€ã§çµå£åŠçããã å¬å71æéç®ã®æåŸã®çšéã¯ãåç©ã殺ãïŒæ
éåã«è¡ãªãããã®è³ã®H2OãK2åã³Ca++å«é
ã®æž¬å®ã«ä»ããã ãã®æ§ãªå®éšæ¡ä»¶äžã§ã®äžæçãªãªãªãŽãšãã¢
ãçºè²è³çŸæ£ãèµ·ãããããããŠãã®è³çŸæ£ã¯æ·±
å»ãªçååŠçé害âæ®ã«Ca++ã€ãªã³ã®èããè³
å èç©ã«ããç¥çµåŠçãªæ§ç¶ã®é害ãç¹åŸŽãšããŠ
ããã ã«ã«ã·ãŠã ãšã³ããªãŒãããã«ãŒã®æ²»ççãªæ
äžã¯ããã®çŸæ£ã®äžæçãªçºçãšå¹²æžããããè¡š
ïŒã«å ±åããçµæã¯YS201ãæµ®è «åå¿ãæå§ãã
ïŒã®è³ããã®æµåºãæå§ãããŸãè³äžã®Ca++
ã€ãªã³ã®èç©ã劚ããããšã瀺ããŠããããŸãäž
æ¹ããã¢ãžãã³ããã«ã«ãžãã³ã®æ§ãªå¥ã®ãžãã
ãããªãžã³ååç©ãšèãããããã®ã¯ããã®å¹å
ããªãã€ãããããŠè¯å¥œãªæŽ»æ§ããã©ããã«ãšãž
ã«ãã¢ãŒã ã«ã¯èŠãããã
YS201ã¯EBsåã³VTã«åºã¥ãã€ã³ããã¯ã¹ãã
ã»ãŒïŒåæžå°ãããããVFâãšããœãŒã
ïŒepisodesïŒæéãšå¹²æžããªãããšãã«ãæãã
ããVFã瀺ãã©ããã®ããŒã»ã³ããŒãžã¯1.5mgïŒ
Kg-1ã§èããæžå°ããŠããããšãæããã«ãªã€
ããå埪ç°ã«ãã€ãŠã¯ã7.5åã³15mgïŒKg-1ã®
YS201ã¯äœãããæ©æECGé害ãèããäœäžã
ããã¯ã©ã³ãã¹ïŒclampsïŒã解é€ãããèæ ®ã«
å ¥ãããã©ã¡ãŒã¿ã¯ãã¹ãŠæžå°ãæ»äº¡ã¯15mgïŒKg
-1ïŒïŒ°ïŒ0.02ïŒã§å®å šã«æå§ãããã ã©ããã§ã®äžæçãªè³ãªãªãŽãšãã¢
ïŒoligoemiaïŒ ãCirculation et Metabolis du CerveauïŒã
63â79ããJohn Libbey Eurotext Publ.ïŒ1983ïŒ
ã«ãã«ããšã€ãã¯ã¹ã«ãã説æãããæ¹æ³ãã60
åã®éäž¡åŽé žåèçµçŽ®ããçŽ10é±ã®éã¹ãã©ã°â
ããŠã¬ã€ã©ãããçšããŠè¡ãªã€ããåç©ããçµçŽ®
åŸïŒæéåŸã«éå§ããã¹ã«ã©ãŒçšéã§ãïŒæ¥éã
ïŒæ¥ïŒåãè©Šéšè¬å€ã§çµå£åŠçããã å¬å71æéç®ã®æåŸã®çšéã¯ãåç©ã殺ãïŒæ
éåã«è¡ãªãããã®è³ã®H2OãK2åã³Ca++å«é
ã®æž¬å®ã«ä»ããã ãã®æ§ãªå®éšæ¡ä»¶äžã§ã®äžæçãªãªãªãŽãšãã¢
ãçºè²è³çŸæ£ãèµ·ãããããããŠãã®è³çŸæ£ã¯æ·±
å»ãªçååŠçé害âæ®ã«Ca++ã€ãªã³ã®èããè³
å èç©ã«ããç¥çµåŠçãªæ§ç¶ã®é害ãç¹åŸŽãšããŠ
ããã ã«ã«ã·ãŠã ãšã³ããªãŒãããã«ãŒã®æ²»ççãªæ
äžã¯ããã®çŸæ£ã®äžæçãªçºçãšå¹²æžããããè¡š
ïŒã«å ±åããçµæã¯YS201ãæµ®è «åå¿ãæå§ãã
ïŒã®è³ããã®æµåºãæå§ãããŸãè³äžã®Ca++
ã€ãªã³ã®èç©ã劚ããããšã瀺ããŠããããŸãäž
æ¹ããã¢ãžãã³ããã«ã«ãžãã³ã®æ§ãªå¥ã®ãžãã
ãããªãžã³ååç©ãšèãããããã®ã¯ããã®å¹å
ããªãã€ãããããŠè¯å¥œãªæŽ»æ§ããã©ããã«ãšãž
ã«ãã¢ãŒã ã«ã¯èŠãããã
ãè¡šã
ãè¡šã
ïŒå¯Ÿå¯Ÿç
§ïŒïŒïŒå¯Ÿãã¹ãâãªã¬ãŽãšããã¯
å¯Ÿç §
ç©æ¥µçã«ææã«ããã¢ã«ã¢ããã®ã¢ããã€ã©ã
ã·ãŒæ§ã®è³åçž®ã«å¯ŸããYS201æäžã®å¹æ ããŒãã¬ã€ã¢ã«ã¢ããã«ãè ¹è å ïŒ100ïœïœïŒ
ãšç®äžïŒ100ïœïœïŒãšã§ãããããããã€ãè£äœ
è¬50ÎŒlãšäžç·ã«ã泚å°ããŠãåµã¢ã«ããã³ïŒOAïŒ
ã«å¯Ÿããç©æ¥µçã«ææã«ããããã®ç©æ¥µçæææ
äœåŸïŒé±éãå®éšãè¡ãªã€ãããã®éãåç©ã¯çŽ
600â700ïœã®äœéã«éããããŠã¬ã¿ã³ïŒ1.25ïœïŒ
Kg-1i.p.ïŒã§éº»é ãããèªç¶åŒåžã«ãŸããããè³
åçž®ã®ãã©ã€ã·ãŠã®ç©ºæ°èéèšåã³ãã¬ãœã°ã©ã
ãŽãã«ãïŒæ床ïŒâ50cmïŒã§èšé²ãä¹ã枬å®
ãã次èšãã©ã¡ãŒã¿ãèšç®ããã âåžæ°éïŒi.v.ïŒïŒml âåŒæ°éïŒe.v.ïŒïŒml âïœïŒi.v.ïŒïŒåŒæ°éã®äŒæ¯å€ã«ã€ããŠã®å·®ïŒOAåŠ
çã«å ã ã€ãŠã®ïŒ âïŒåéã®åŒåžéïŒïœïŒv.ïŒïŒmlïŒmin âåŒåžé »åºŠïŒr.t.ïŒïŒæ床ïŒmin âãã©ã³ã¹èºå§ïŒTrans ïŒïŒcmH2O âèºå¿è«ŸïŒp.c.ïŒïŒmlïŒcmH2O âèºæµæïŒp.r.ïŒïŒcmH2OïŒmlïŒsec. ã¢ããã€ã©ãã·ãŒæ§è³åçž®ã¯ææã«ããã¢ã«ã¢
ããã«ãOAâé泚ïŒïŒmgïŒKgïŒåŠçããŠçèµ·ã
ãããåç©ã¯ãã¹ãŠãOAâæäžã®ïŒååã«ãæ
ãã¹ã¿ãã³æ§ã¡ãã©ãã³ïŒ1.0mgïŒKgi.v.ïŒã§åŠç
ããããã¹ãååç©ïŒYS201ïŒåã¯æ äœïŒèžç
æ°ŽïŒãOAâåŠçã«å ã ã€ãŠãïŒmlïŒKgã®å®¹éã§
è ¹è å ã«æ³šå°ããã枬å®ã¯OAâåŠçåŸãåïŒ
ïŒãïŒãïŒãïŒãïŒã10åã³15ååŸã«è¡ãªã€ãã
åŒç §å€âTOâã¯ã¢ãã€ã©ãã·ãŒã·ãšãã¯ãšçŽ
åãå³ã¡YS201ã泚å°ããããš15ååŸã«èæ ®ãã
ããYS201ã®ïŒã€ã®çšéãå³ã¡åïŒå¹ã®ã¢ã«ã¢ã
ãã«ïŒåã³10mgïŒKgã«ã€ããŠæ€èšããã çµæã¯ïŒã·ãªãºïŒã³ã³ãããŒã«âYS201ïŒïŒ
mgïŒKgãš10mgïŒKgïŒãã¹ãŠãèæ ®ããŠã®å€åã®ã°
ããŒãã«åæãçšããŠè¡ãªã€ããçµ±èšçãªå·®ç°ã
ã¬ãã«âŠ0.05ã«åºçŸãããšãããªãŒã¹ã ã·ã°
ããã€ã«ã³ã ãžãã¢ã¬ã³ã¹ïŒLSDïŒãã¹ããã
ãã®ã·ãªãŒãºãä»ã®äºã€ã®éã«äžã€ã眮ãæ§ã«è¡
ãªã€ãã åŸãããçµæã¯YS201ã®å¹æããèºã®åŒŸåæ§ã
ã®ãã®ã«å¯Ÿããæå°çµæã§ãïŒmgïŒKgã«æŒããŠç¹
城ã¥ããããããšã瀺ããŠãããããããªããã
èºã®ç²åŒŸæ§ã«å¯Ÿããããã®éãããå¹æã¯ãåžæ°
éåã³åŒæ°éã®å¢å€§ã«ããè³åçž®ã®è£åãå¯èœã«
ãããã®ã§ãããå察ã«ã10mgïŒKgã§ã¯ãYS201
ã¯ãèºè£åãå¢å€§ããèºåèæµæãæžå°ãããã
ãšã«ãããçŽæ¥äœçšããæ§ã«æãããããã®å¹æ
ã¯å€åã®ã°ããŒãã«ãªåæã«ããå åæçœã«èšŒæ
ãããããšãåºæ¥ããåŒæ°éåã¯åžæ°éããã®çš
éã§å¢å€§ããŠããªããšããäºå®ã¯ãååŠç
ïŒdynamicïŒå¿è«Ÿã«å¯ŸããYS201å¹æã®çŽæ¥ã®çµ
æã§ããããããŠååŠçïŒdynamicïŒå¿è«Ÿã¯åŒæ°
éã«ããè£æ£çãªæ©èœãåé¿ããã®ã§ããã èŠããã«ãYS201ã§åŸãããçµæã¯ããã®åå
ç©ãã¢ã«ã¢ããã«ã¢ããã€ã©ãã·ã€æ§è³åçž®ãèµ·
ãããåµã¢ã«ããã³âæäžã«å¯Ÿããä¿è·ããããš
ãåºæ¥ãããšã瀺ããŠããããã®æ§ãªæ§è³ªã¯ãžã
ããããªãžã³ã°ã«ãŒãåã¯ãã©ããã«åã¯ãžã«ã
ã¢ãŒã æ§æ§é ã®ã©ã®ã«ã«ã·ãŠã æ®æå€ã«ã€ããŠã
説æãããŠããªã€ããã®ã§ããã è¬çã«ã€ãããã¯åã³çç©æå¹æ§ YS201å¡©é žå¡©ãéèå åã¯çµå£çã«ç¬ã«ããã
ããïŒmgåã³10mgïŒKgãæäžããã éèæäžåŸãYS201æ¿åºŠã®äžèœã¯å žåçã«ïŒæ
æ°ïŒbiexponenitalïŒã§ãã€ããæåºã®å¹³ååæž
æã¯88åã§ãã€ãã çµå£æäžåŸãè¡æŒ¿æ¿åºŠæéãããã€ã«ã«ããã
ã³ã³ããªãŒïŒcondaryïŒããŒã¯ã¯è žè茪åãã
YS201ã®ååšãæšå®ãããã148.3minãªãæåºã®
æ¡å€§ããå¹³åèŠæãåæžæãçµå£æäžã«ãã瀺ã
ãããå¹³åã®æ倧æ¿åºŠã¯284nïœïŒmgã§ããããšã
ãããå¹³åã®AUCã64873.6nïœïŒml-1minã§ãã
ããšãå€ã€ãããããã®çµæã¯ãã«ã«ãžãã³ã®å
ãçšéïŒCmaxïŒ220nïœïŒmlåã³ACUïŒ76600n
ïœïŒKg-1minïŒã§ã®ç¬ã«åŸãããçµæã«å¯Ÿæ¯ã§ã
ããå¹³åã®èŠæãã®çç©æå¹æ§ã®ãããã©ã¯ã·ãš
ã³ã¯19.4ïŒ ã§ãã€ãã æ§ç¶ãã©ã³ãã¢ã§ã®çµå£æäžã«ããYS201ã®ç
ç©æå¹æ§ ãã®ç 究ã¯26â43æã®ïŒäººã®ç·æ§ã«ã€ããŠå®æœ
ããã è¬åŠçã«ã€ããã¯ç 究ã¯ã¢ã¯ãŒããªæäžãšå¢é
æäžãšã®ïŒã€ã«ã€ããŠè¡ãªãããã ã¢ã¯ãŒããªæäž åãã©ã³ãã¢ã¯ãYS201ã®20mgã«ãã»ã«ïŒåã
äžæ¯ã®ã°ã©ã¹ã®æ°Žãšäžç·ã«æåããã ãã®åŸã®éèè¡æ¶²ãµã³ãã«ãæäžåŸã15â30å
åã³1.0â1.5â2.0â4.0â6.0â8.æéã«æ¡åããã å¢éæäž åãïŒåã®ãã©ã³ãã¢ãæåã®æäžã®åŸã
YS201ãæäžéãå€ãããŠ30â40â50mgã®çšéã§
åŠçããã è¡æ¶²ãµã³ãã«ãæåŸã®åŠçã®ïŒâïŒâïŒâ12æ
éåŸã«æ¡åããã ãã®ãŸãŸYS201ã®è¡æŒ¿ã¬ãã«ã¯ç¹å¥ã®HPLCæ³
ã§æ€æ»ããã åŸãããè¬åŠã«ã€ããã㯠ãã©ã¡ãŒã¿ã¯æ¬¡
èšãè¡šïŒã«å ±åãããŠããã
å¯Ÿç §
ç©æ¥µçã«ææã«ããã¢ã«ã¢ããã®ã¢ããã€ã©ã
ã·ãŒæ§ã®è³åçž®ã«å¯ŸããYS201æäžã®å¹æ ããŒãã¬ã€ã¢ã«ã¢ããã«ãè ¹è å ïŒ100ïœïœïŒ
ãšç®äžïŒ100ïœïœïŒãšã§ãããããããã€ãè£äœ
è¬50ÎŒlãšäžç·ã«ã泚å°ããŠãåµã¢ã«ããã³ïŒOAïŒ
ã«å¯Ÿããç©æ¥µçã«ææã«ããããã®ç©æ¥µçæææ
äœåŸïŒé±éãå®éšãè¡ãªã€ãããã®éãåç©ã¯çŽ
600â700ïœã®äœéã«éããããŠã¬ã¿ã³ïŒ1.25ïœïŒ
Kg-1i.p.ïŒã§éº»é ãããèªç¶åŒåžã«ãŸããããè³
åçž®ã®ãã©ã€ã·ãŠã®ç©ºæ°èéèšåã³ãã¬ãœã°ã©ã
ãŽãã«ãïŒæ床ïŒâ50cmïŒã§èšé²ãä¹ã枬å®
ãã次èšãã©ã¡ãŒã¿ãèšç®ããã âåžæ°éïŒi.v.ïŒïŒml âåŒæ°éïŒe.v.ïŒïŒml âïœïŒi.v.ïŒïŒåŒæ°éã®äŒæ¯å€ã«ã€ããŠã®å·®ïŒOAåŠ
çã«å ã ã€ãŠã®ïŒ âïŒåéã®åŒåžéïŒïœïŒv.ïŒïŒmlïŒmin âåŒåžé »åºŠïŒr.t.ïŒïŒæ床ïŒmin âãã©ã³ã¹èºå§ïŒTrans ïŒïŒcmH2O âèºå¿è«ŸïŒp.c.ïŒïŒmlïŒcmH2O âèºæµæïŒp.r.ïŒïŒcmH2OïŒmlïŒsec. ã¢ããã€ã©ãã·ãŒæ§è³åçž®ã¯ææã«ããã¢ã«ã¢
ããã«ãOAâé泚ïŒïŒmgïŒKgïŒåŠçããŠçèµ·ã
ãããåç©ã¯ãã¹ãŠãOAâæäžã®ïŒååã«ãæ
ãã¹ã¿ãã³æ§ã¡ãã©ãã³ïŒ1.0mgïŒKgi.v.ïŒã§åŠç
ããããã¹ãååç©ïŒYS201ïŒåã¯æ äœïŒèžç
æ°ŽïŒãOAâåŠçã«å ã ã€ãŠãïŒmlïŒKgã®å®¹éã§
è ¹è å ã«æ³šå°ããã枬å®ã¯OAâåŠçåŸãåïŒ
ïŒãïŒãïŒãïŒãïŒã10åã³15ååŸã«è¡ãªã€ãã
åŒç §å€âTOâã¯ã¢ãã€ã©ãã·ãŒã·ãšãã¯ãšçŽ
åãå³ã¡YS201ã泚å°ããããš15ååŸã«èæ ®ãã
ããYS201ã®ïŒã€ã®çšéãå³ã¡åïŒå¹ã®ã¢ã«ã¢ã
ãã«ïŒåã³10mgïŒKgã«ã€ããŠæ€èšããã çµæã¯ïŒã·ãªãºïŒã³ã³ãããŒã«âYS201ïŒïŒ
mgïŒKgãš10mgïŒKgïŒãã¹ãŠãèæ ®ããŠã®å€åã®ã°
ããŒãã«åæãçšããŠè¡ãªã€ããçµ±èšçãªå·®ç°ã
ã¬ãã«âŠ0.05ã«åºçŸãããšãããªãŒã¹ã ã·ã°
ããã€ã«ã³ã ãžãã¢ã¬ã³ã¹ïŒLSDïŒãã¹ããã
ãã®ã·ãªãŒãºãä»ã®äºã€ã®éã«äžã€ã眮ãæ§ã«è¡
ãªã€ãã åŸãããçµæã¯YS201ã®å¹æããèºã®åŒŸåæ§ã
ã®ãã®ã«å¯Ÿããæå°çµæã§ãïŒmgïŒKgã«æŒããŠç¹
城ã¥ããããããšã瀺ããŠãããããããªããã
èºã®ç²åŒŸæ§ã«å¯Ÿããããã®éãããå¹æã¯ãåžæ°
éåã³åŒæ°éã®å¢å€§ã«ããè³åçž®ã®è£åãå¯èœã«
ãããã®ã§ãããå察ã«ã10mgïŒKgã§ã¯ãYS201
ã¯ãèºè£åãå¢å€§ããèºåèæµæãæžå°ãããã
ãšã«ãããçŽæ¥äœçšããæ§ã«æãããããã®å¹æ
ã¯å€åã®ã°ããŒãã«ãªåæã«ããå åæçœã«èšŒæ
ãããããšãåºæ¥ããåŒæ°éåã¯åžæ°éããã®çš
éã§å¢å€§ããŠããªããšããäºå®ã¯ãååŠç
ïŒdynamicïŒå¿è«Ÿã«å¯ŸããYS201å¹æã®çŽæ¥ã®çµ
æã§ããããããŠååŠçïŒdynamicïŒå¿è«Ÿã¯åŒæ°
éã«ããè£æ£çãªæ©èœãåé¿ããã®ã§ããã èŠããã«ãYS201ã§åŸãããçµæã¯ããã®åå
ç©ãã¢ã«ã¢ããã«ã¢ããã€ã©ãã·ã€æ§è³åçž®ãèµ·
ãããåµã¢ã«ããã³âæäžã«å¯Ÿããä¿è·ããããš
ãåºæ¥ãããšã瀺ããŠããããã®æ§ãªæ§è³ªã¯ãžã
ããããªãžã³ã°ã«ãŒãåã¯ãã©ããã«åã¯ãžã«ã
ã¢ãŒã æ§æ§é ã®ã©ã®ã«ã«ã·ãŠã æ®æå€ã«ã€ããŠã
説æãããŠããªã€ããã®ã§ããã è¬çã«ã€ãããã¯åã³çç©æå¹æ§ YS201å¡©é žå¡©ãéèå åã¯çµå£çã«ç¬ã«ããã
ããïŒmgåã³10mgïŒKgãæäžããã éèæäžåŸãYS201æ¿åºŠã®äžèœã¯å žåçã«ïŒæ
æ°ïŒbiexponenitalïŒã§ãã€ããæåºã®å¹³ååæž
æã¯88åã§ãã€ãã çµå£æäžåŸãè¡æŒ¿æ¿åºŠæéãããã€ã«ã«ããã
ã³ã³ããªãŒïŒcondaryïŒããŒã¯ã¯è žè茪åãã
YS201ã®ååšãæšå®ãããã148.3minãªãæåºã®
æ¡å€§ããå¹³åèŠæãåæžæãçµå£æäžã«ãã瀺ã
ãããå¹³åã®æ倧æ¿åºŠã¯284nïœïŒmgã§ããããšã
ãããå¹³åã®AUCã64873.6nïœïŒml-1minã§ãã
ããšãå€ã€ãããããã®çµæã¯ãã«ã«ãžãã³ã®å
ãçšéïŒCmaxïŒ220nïœïŒmlåã³ACUïŒ76600n
ïœïŒKg-1minïŒã§ã®ç¬ã«åŸãããçµæã«å¯Ÿæ¯ã§ã
ããå¹³åã®èŠæãã®çç©æå¹æ§ã®ãããã©ã¯ã·ãš
ã³ã¯19.4ïŒ ã§ãã€ãã æ§ç¶ãã©ã³ãã¢ã§ã®çµå£æäžã«ããYS201ã®ç
ç©æå¹æ§ ãã®ç 究ã¯26â43æã®ïŒäººã®ç·æ§ã«ã€ããŠå®æœ
ããã è¬åŠçã«ã€ããã¯ç 究ã¯ã¢ã¯ãŒããªæäžãšå¢é
æäžãšã®ïŒã€ã«ã€ããŠè¡ãªãããã ã¢ã¯ãŒããªæäž åãã©ã³ãã¢ã¯ãYS201ã®20mgã«ãã»ã«ïŒåã
äžæ¯ã®ã°ã©ã¹ã®æ°Žãšäžç·ã«æåããã ãã®åŸã®éèè¡æ¶²ãµã³ãã«ãæäžåŸã15â30å
åã³1.0â1.5â2.0â4.0â6.0â8.æéã«æ¡åããã å¢éæäž åãïŒåã®ãã©ã³ãã¢ãæåã®æäžã®åŸã
YS201ãæäžéãå€ãããŠ30â40â50mgã®çšéã§
åŠçããã è¡æ¶²ãµã³ãã«ãæåŸã®åŠçã®ïŒâïŒâïŒâ12æ
éåŸã«æ¡åããã ãã®ãŸãŸYS201ã®è¡æŒ¿ã¬ãã«ã¯ç¹å¥ã®HPLCæ³
ã§æ€æ»ããã åŸãããè¬åŠã«ã€ããã㯠ãã©ã¡ãŒã¿ã¯æ¬¡
èšãè¡šïŒã«å ±åãããŠããã
ãè¡šã
ïŒ ã¢ããŠãŒããªæäžã«ãã
ïŒïŒ å¢éæäžã«ãã
ãã®ã¢ããŠãŒãç 究ã«ãããè¡æŒ¿ç¶æ³ã¯90åãª
ãå¹³åæ倧ã蚌æ ãšããŠãYS201ã®æ¥éãªåžå
ã瀺ããŠãããããŒã¯ã®è¡æŒ¿æ°Žæºã®å¹³åå€ã¯
57.25nïœïŒml±2.65ïŒÂ±S.EïŒã§ãã€ãã å¢éã®ååžåã³ææ³ã®çžã«å¯Ÿå¿ããŠãè¡æŒ¿ã¬ã
ã«ã¯äœäžããã1/2etã®å¹³åå€ã¯ã1.8æé±
0.65S.D.ã§ãã€ãã ïŒæéåŸã«ãã®ãŸãŸè¬å€ããªãè¡æŒ¿äžã«ååšã
ãŠããã è¬å€ç 究ã«ãã€ãŠã¯ãå¢éã§ã®æçµæ²»çã®ïŒæ
éåŸã«ãããšã®ãŸãŸã®è¬ç©ã®è¡æŒ¿ã¬ãã«ãã¢ããŠ
ãŒãåŠçåŸã®åãæéã«ãããæäžå€ãšæ¯ã¹ãŠïŒ
åäžæ¹ã«ãã€ãã æäžïŒæéåŸã«ã¯ãè¡æŒ¿ã¬ãã«ã¯ãããŒã¯ã«æ¯
ã¹ãŠ1/2ã«æžå°ããã æäžã®12æéåŸãYS201ã¯ããªããã®ãŸãŸã®åœ¢
ã§è¡æŒ¿äžã«ååšããŠããã åºç»åæã®çµæã«ãããšããã®ãŸãŸã®è¬å€ã®è¡
挿ã®ç¶æ³ã¯ã¢ããŠãŒãæäžã§ãå埩æäžã§ããïŒ
ã€ã®ããšãŒãºäžã§äœäžãããããããåè ã®å Ž
åãæ°Žæºã¯ããæ¥éã«äœäžããããããŠããã®ã
ãšã¯ç瞮平åçµæ«åæžæãå³ã¡ã¢ããŠãŒããªæäž
åŸã¯1.8æéãå埩æäžã§ã¯4.29æéã«ç€ºãããŠ
ããã ãã®æ§ãªæ°å€ã®å·®ç°ã¯ãå¥ã®ã±ãŒã¹ã§ãå€ãã®
èè ã«ããå ±åãããŠããæ§ã«ãæäžçšéã®å¢å€§
ãšé¢é£ããŠããïŒãçç©è¬åŠåã³é¢é£è¬ç©ã«ã€ã
ããã¯ã¹ãã¯ã°ããŒãžãšã€ããžãŒããã©ã° ã€ã³
ããªãžãšã³ã¹ ãããªã±ãŒã·ãšã³ã¹ãããã«ã
ã³ãã€ãªãã€ãåçã1971ïŒ èšåºç蚱容ç¯å² YS201ã®çµå£æäžã®èš±å®¹ç¯å²ã¯å åã«å€§ããã
å³ã¡ãæ£åžžãªåŒåžæ©èœåã³ãã®ä»ã®çåœãã©ã¡ãŒ
ã¿ãŒã¯åœ±é¿ãåããªãã€ãã å¿èè¡ç®¡æ©èœã«ã€ããŠã¯ãåèå§ã®ç ççå€æŽ
ã¯èŠ³å¯ãããªãã€ããäºäººã®æ£è ïŒNo.3.4.ïŒã«
ã¯ããããä¹ãæž©åã§ã¯ããããéå®ããã硬è³
èéèæŽã®åŸèïŒsnus bradycardiaïŒãèšé²ã
ããã æ¿å®€èªå°æéïŒPRééïŒã¯äºäººã®æ£è ïŒNo.
1.2.ïŒã§å ãã«å»¶é·ããããã®æ§ãªééã¯æ£è No.
ïŒã§ã¯0.14ã0.16sec.ã®å»¶é·ã§ãæ£è No.ïŒã§ã¯0.16
ã0.18sec.ã§ãã€ãã ãããã®å€æŽã¯ãç¹æ®èªå°ã·ã¹ãã ã®äžæ¹éšäœ
ãžã®YS201ã®ã«ã«ã·ãŠã æ®æäœçšã«åœç¶é¢é£ãã
ãã®ã§ããã ãããã®åŸãããçµæã¯ãã¹ãŠãYS201ã匷å
ãªã«ã«ã·ãŠã æ®æå€ã§ããããŸããã¢ã³ããã€ã
ã³ïŒ1985ãArzn.Forsch.I.Drug Research 35
ïŒïŒïŒïŒNr.IaïŒ298â301ïŒã«ããå®çŸ©ã«ããã«ã«
ã·ãŠã âãªãŒããŒããŒã ãããã«ãŒã§ããããš
ã瀺ããŠããããã®è¬ç©ã¯å¿èäžã®ã«ã«ã·ãŠã å«
éã®å¢å€§ãæå§ããŠãæ¢å¡éšäœãæžå°ãããããš
ã«ããå¿è貧è¡çŸæ£ã®æ²»çã«äœ¿çšã§ãããŸãè³å®€
äžæŽèçºäœæ§è³å®€é »æçã®æ²»çããšã¯ããã«ã¯ãª
èæåã³æå€èæã®æ²»çåã³çå¿çã«ãããå¿è
ãã¢ããªã¬ãŒã·ãšã³ã«ããæ¥æ»äºé²ã«äœ¿çšã§ã
ãããã®è¬ç©ã¯ãåŸã€ãŠè³åèæ£çž®ã®æ²»çåã³è³
貧è¡ã®çµæãšããŠã®ã«ã«ã·ãŠã ã®èç©å¢å€§ãæžå°
ãããããã¹ãããŒã¯ïŒstorokeïŒã®æ©ææ²»çã«
çšããããã ãã®è¬ç©ã¯ãŸããéèŠãªé«è¡å§ã®æ²»çã«çšãã
ããããããã¯ãã®ãã®ãMABPãSABPåã³
DABPãå®æ¯æ¡ä»¶äžã§äœäžãããã ãã§ãªãã
人ã®æ¬è³ªçãªé«è¡å§ã®ç¹åŸŽã§ããå¿é ãåªåã«å¯Ÿ
ããé«è¡å§æ§å¿çãæå§ããããã§ããã ãã®è¬ç©ã¯ããŸãã¢ã¬ã«ã®ãŒæ§ã®åæ¯ã®æ²»çã«
ã䜿çšã§ããããããŠåŒ·èª¿ãããã¹ãç¹ã¯ãèºã
æ°ç®¡æ¯ã«å¯Ÿããå¹æãå¿èã®äœæ¥ã«åœ±é¿ãäžãã
ããšãªãã«ãéæã§ããããšã§ããããã®ããšã¯
ãã®çŸç ã®åŠçã«å®éã«çšãããããªã³ãžãšã¹ã
ã©ãŒãŒãŒé»å®³å€ã«ã€ããŠèŠ³å¯ãããã 以äžã®YS201ã®è¬åŠçãªå šæ§ç¶ïŒprofileïŒã¯ã
ãžãããããªãžã³ç³»ã«å±ããä»ã®ã«ã«ã·ãŠã æ®æ
å€ã®ãããšãèããçžç°ããŠããããšãå€ãã è¬åŠçã«èš±å®¹ã§ããYS201ã®å¡©ã¯ãå®è³ªçã«é
é¢ã®å¡©åºãšåãå¹æãæã€ãŠããã ããå Žåã«äœ¿çšãããé žãå€ããããšã«ããåŸ
ãããå¡©ã¯é«ãå®å®æ§ãé«ã溶解æ§ãäœã溶解
æ§ãæçµæ¶æ§ãäžå¿«ãªå³ã®ãªãããšçã«ããæå©
ã§ãããããããã¯éé¢å¡©åºã®äž»ããçç©åŠçäœ
çšã«æ¯ã¹ããšå¯æ¬¡çã§ããã ãããŠãã®å¡©ãã€ããã®ã«äœ¿çšããé žã®æ§è³ªãš
ã¯é¢ä¿ããªãã æ²»çã«äœ¿çšããã«ã¯ãYS201åã¯ãã®å¡©ã¯æ®é
ã®æ äœãè£å©å€ãåã³æ¹æ³ãçšããŠé ãããçµ
å£ãè žç®¡å€ãŸãã¯çµå£çšçµæç©ã«é©åœãªè¬å€çµæ
ç©ãšããŠæäžã§ããã ãããçµæç©ã®äŸãšããŠã¯ãã«ãã»ã«ãé å€ã
ã·ããããé¡ç²ãç¶å ¥ãçãå«ãããæ®ã«çµå£ç
ã§éè溶æ§ã§è žæº¶æ§ã®è£œå€ã奜ãŸããããªããª
ãããããå€åã¯èéæµææ§ã®é垞補å€ã®æäžã«
ãã€ãŠåŸããããããé¥ãã«é«ãçç©æŽ»æ§ã瀺ã
ããã§ãã äžæ¥ã®çšéã¯èšåºæ€æ»åã³æ£è æ¡ä»¶ïŒæ§ãäœé
åã³å¹Žä»€ïŒã«ãã€ãŠæ±ºãŸãããããŠãæ®éïŒâïŒ
åã®æäžã§50â500mgã®ç¯å²ã§ããã æ¬çºæã®ååç©YS201ãšãã€ãšã«ç€Ÿã®ç¹éæ49
â14614å·å ¬å ±ã«èšèŒã®ååç©ãšã®äœçšå¹æãæ¯
èŒããã 次ã®è©Šéšã§ïŒçš®ã®ååç©ãæ¯èŒããã (a) çµå£æäžåŸã®éåã³éã©ããã«ãããæ¯æ§
ïŒå矀ã§åç©10å¹äœ¿çšïŒ (b) ãŠãµã®å€§åèã®åçž®ã«å¯Ÿããäœçš ïŒ ã©ããã«ãããæ¯æ§
ïŒïŒ å¢éæäžã«ãã
ãã®ã¢ããŠãŒãç 究ã«ãããè¡æŒ¿ç¶æ³ã¯90åãª
ãå¹³åæ倧ã蚌æ ãšããŠãYS201ã®æ¥éãªåžå
ã瀺ããŠãããããŒã¯ã®è¡æŒ¿æ°Žæºã®å¹³åå€ã¯
57.25nïœïŒml±2.65ïŒÂ±S.EïŒã§ãã€ãã å¢éã®ååžåã³ææ³ã®çžã«å¯Ÿå¿ããŠãè¡æŒ¿ã¬ã
ã«ã¯äœäžããã1/2etã®å¹³åå€ã¯ã1.8æé±
0.65S.D.ã§ãã€ãã ïŒæéåŸã«ãã®ãŸãŸè¬å€ããªãè¡æŒ¿äžã«ååšã
ãŠããã è¬å€ç 究ã«ãã€ãŠã¯ãå¢éã§ã®æçµæ²»çã®ïŒæ
éåŸã«ãããšã®ãŸãŸã®è¬ç©ã®è¡æŒ¿ã¬ãã«ãã¢ããŠ
ãŒãåŠçåŸã®åãæéã«ãããæäžå€ãšæ¯ã¹ãŠïŒ
åäžæ¹ã«ãã€ãã æäžïŒæéåŸã«ã¯ãè¡æŒ¿ã¬ãã«ã¯ãããŒã¯ã«æ¯
ã¹ãŠ1/2ã«æžå°ããã æäžã®12æéåŸãYS201ã¯ããªããã®ãŸãŸã®åœ¢
ã§è¡æŒ¿äžã«ååšããŠããã åºç»åæã®çµæã«ãããšããã®ãŸãŸã®è¬å€ã®è¡
挿ã®ç¶æ³ã¯ã¢ããŠãŒãæäžã§ãå埩æäžã§ããïŒ
ã€ã®ããšãŒãºäžã§äœäžãããããããåè ã®å Ž
åãæ°Žæºã¯ããæ¥éã«äœäžããããããŠããã®ã
ãšã¯ç瞮平åçµæ«åæžæãå³ã¡ã¢ããŠãŒããªæäž
åŸã¯1.8æéãå埩æäžã§ã¯4.29æéã«ç€ºãããŠ
ããã ãã®æ§ãªæ°å€ã®å·®ç°ã¯ãå¥ã®ã±ãŒã¹ã§ãå€ãã®
èè ã«ããå ±åãããŠããæ§ã«ãæäžçšéã®å¢å€§
ãšé¢é£ããŠããïŒãçç©è¬åŠåã³é¢é£è¬ç©ã«ã€ã
ããã¯ã¹ãã¯ã°ããŒãžãšã€ããžãŒããã©ã° ã€ã³
ããªãžãšã³ã¹ ãããªã±ãŒã·ãšã³ã¹ãããã«ã
ã³ãã€ãªãã€ãåçã1971ïŒ èšåºç蚱容ç¯å² YS201ã®çµå£æäžã®èš±å®¹ç¯å²ã¯å åã«å€§ããã
å³ã¡ãæ£åžžãªåŒåžæ©èœåã³ãã®ä»ã®çåœãã©ã¡ãŒ
ã¿ãŒã¯åœ±é¿ãåããªãã€ãã å¿èè¡ç®¡æ©èœã«ã€ããŠã¯ãåèå§ã®ç ççå€æŽ
ã¯èŠ³å¯ãããªãã€ããäºäººã®æ£è ïŒNo.3.4.ïŒã«
ã¯ããããä¹ãæž©åã§ã¯ããããéå®ããã硬è³
èéèæŽã®åŸèïŒsnus bradycardiaïŒãèšé²ã
ããã æ¿å®€èªå°æéïŒPRééïŒã¯äºäººã®æ£è ïŒNo.
1.2.ïŒã§å ãã«å»¶é·ããããã®æ§ãªééã¯æ£è No.
ïŒã§ã¯0.14ã0.16sec.ã®å»¶é·ã§ãæ£è No.ïŒã§ã¯0.16
ã0.18sec.ã§ãã€ãã ãããã®å€æŽã¯ãç¹æ®èªå°ã·ã¹ãã ã®äžæ¹éšäœ
ãžã®YS201ã®ã«ã«ã·ãŠã æ®æäœçšã«åœç¶é¢é£ãã
ãã®ã§ããã ãããã®åŸãããçµæã¯ãã¹ãŠãYS201ã匷å
ãªã«ã«ã·ãŠã æ®æå€ã§ããããŸããã¢ã³ããã€ã
ã³ïŒ1985ãArzn.Forsch.I.Drug Research 35
ïŒïŒïŒïŒNr.IaïŒ298â301ïŒã«ããå®çŸ©ã«ããã«ã«
ã·ãŠã âãªãŒããŒããŒã ãããã«ãŒã§ããããš
ã瀺ããŠããããã®è¬ç©ã¯å¿èäžã®ã«ã«ã·ãŠã å«
éã®å¢å€§ãæå§ããŠãæ¢å¡éšäœãæžå°ãããããš
ã«ããå¿è貧è¡çŸæ£ã®æ²»çã«äœ¿çšã§ãããŸãè³å®€
äžæŽèçºäœæ§è³å®€é »æçã®æ²»çããšã¯ããã«ã¯ãª
èæåã³æå€èæã®æ²»çåã³çå¿çã«ãããå¿è
ãã¢ããªã¬ãŒã·ãšã³ã«ããæ¥æ»äºé²ã«äœ¿çšã§ã
ãããã®è¬ç©ã¯ãåŸã€ãŠè³åèæ£çž®ã®æ²»çåã³è³
貧è¡ã®çµæãšããŠã®ã«ã«ã·ãŠã ã®èç©å¢å€§ãæžå°
ãããããã¹ãããŒã¯ïŒstorokeïŒã®æ©ææ²»çã«
çšããããã ãã®è¬ç©ã¯ãŸããéèŠãªé«è¡å§ã®æ²»çã«çšãã
ããããããã¯ãã®ãã®ãMABPãSABPåã³
DABPãå®æ¯æ¡ä»¶äžã§äœäžãããã ãã§ãªãã
人ã®æ¬è³ªçãªé«è¡å§ã®ç¹åŸŽã§ããå¿é ãåªåã«å¯Ÿ
ããé«è¡å§æ§å¿çãæå§ããããã§ããã ãã®è¬ç©ã¯ããŸãã¢ã¬ã«ã®ãŒæ§ã®åæ¯ã®æ²»çã«
ã䜿çšã§ããããããŠåŒ·èª¿ãããã¹ãç¹ã¯ãèºã
æ°ç®¡æ¯ã«å¯Ÿããå¹æãå¿èã®äœæ¥ã«åœ±é¿ãäžãã
ããšãªãã«ãéæã§ããããšã§ããããã®ããšã¯
ãã®çŸç ã®åŠçã«å®éã«çšãããããªã³ãžãšã¹ã
ã©ãŒãŒãŒé»å®³å€ã«ã€ããŠèŠ³å¯ãããã 以äžã®YS201ã®è¬åŠçãªå šæ§ç¶ïŒprofileïŒã¯ã
ãžãããããªãžã³ç³»ã«å±ããä»ã®ã«ã«ã·ãŠã æ®æ
å€ã®ãããšãèããçžç°ããŠããããšãå€ãã è¬åŠçã«èš±å®¹ã§ããYS201ã®å¡©ã¯ãå®è³ªçã«é
é¢ã®å¡©åºãšåãå¹æãæã€ãŠããã ããå Žåã«äœ¿çšãããé žãå€ããããšã«ããåŸ
ãããå¡©ã¯é«ãå®å®æ§ãé«ã溶解æ§ãäœã溶解
æ§ãæçµæ¶æ§ãäžå¿«ãªå³ã®ãªãããšçã«ããæå©
ã§ãããããããã¯éé¢å¡©åºã®äž»ããçç©åŠçäœ
çšã«æ¯ã¹ããšå¯æ¬¡çã§ããã ãããŠãã®å¡©ãã€ããã®ã«äœ¿çšããé žã®æ§è³ªãš
ã¯é¢ä¿ããªãã æ²»çã«äœ¿çšããã«ã¯ãYS201åã¯ãã®å¡©ã¯æ®é
ã®æ äœãè£å©å€ãåã³æ¹æ³ãçšããŠé ãããçµ
å£ãè žç®¡å€ãŸãã¯çµå£çšçµæç©ã«é©åœãªè¬å€çµæ
ç©ãšããŠæäžã§ããã ãããçµæç©ã®äŸãšããŠã¯ãã«ãã»ã«ãé å€ã
ã·ããããé¡ç²ãç¶å ¥ãçãå«ãããæ®ã«çµå£ç
ã§éè溶æ§ã§è žæº¶æ§ã®è£œå€ã奜ãŸããããªããª
ãããããå€åã¯èéæµææ§ã®é垞補å€ã®æäžã«
ãã€ãŠåŸããããããé¥ãã«é«ãçç©æŽ»æ§ã瀺ã
ããã§ãã äžæ¥ã®çšéã¯èšåºæ€æ»åã³æ£è æ¡ä»¶ïŒæ§ãäœé
åã³å¹Žä»€ïŒã«ãã€ãŠæ±ºãŸãããããŠãæ®éïŒâïŒ
åã®æäžã§50â500mgã®ç¯å²ã§ããã æ¬çºæã®ååç©YS201ãšãã€ãšã«ç€Ÿã®ç¹éæ49
â14614å·å ¬å ±ã«èšèŒã®ååç©ãšã®äœçšå¹æãæ¯
èŒããã 次ã®è©Šéšã§ïŒçš®ã®ååç©ãæ¯èŒããã (a) çµå£æäžåŸã®éåã³éã©ããã«ãããæ¯æ§
ïŒå矀ã§åç©10å¹äœ¿çšïŒ (b) ãŠãµã®å€§åèã®åçž®ã«å¯Ÿããäœçš ïŒ ã©ããã«ãããæ¯æ§
ãè¡šã
ãè¡šã
ïŒ ãŠãµã®å€§åèã®åçž®ã«å¯Ÿããäœçš
 é»äœå·®äœåãã€ã³ãã«äžã®äœçš
K+èªå°åçž®ã®æå¶ç
ãè¡šã
 ã¬ã»ãã¿ãŒäœåãã€ãã«ã®äœçš
ãè¡šã
ååç©ã¯ïœâããããã³ãºã¢ã«ãããããšã
ã«âβâã¢ããã¯ããã³é žãšã¹ãã«åã³ïŒâãã
ãªãžããšã¿ããŒã«ã¢ã»ããŒããã次åŒã«ããåå¿
ãããããšã«ãã補é ãããã ãã®åå¿ã¯ãæ®é溶å€ã®äžååšäžãçŽ90â100
âã®æž©åºŠã§æ°æéãè¡ãªãããã ïœâããããã³ãºã¢ã«ããããšÎ²âã¢ããã¯ã
ãããŒããšã¯åžå Žã§å ¥æã§ãããããããã¯å ¬ç¥
æ¹æ³ã§è£œé ããããšãã§ãããïŒâãããªãžããš
ã¿ããŒã«ã¢ã»ãã¢ã»ããŒãã¯ãœãŒãããªãžãã¡ã¿
ããŒã«ãšãžã±ãã³ãšãã¢ãã³ã®ååšäžã§åå¿ããŠ
æå©ã«è£œé ã§ããã äžèšã®äŸã¯æ¬çºæãæŽã«èª¬æãããã®ã§ãã
ãã決ããŠããããå¶éãããã®ã§ã¯ãªãã å®æœäŸ (a) ïŒâãããªãžããšã¿ããŒã«âã¢ã»ãã¢ã»ããŒ
ã ãžã±ãã³ïŒ8.1mlïŒãïŒâãããªãžããšã¿ã
ãŒã«ïŒ9.36mlïŒãšããªãšãã«ã¢ãã³ïŒ0.05mlïŒ
ãšã«æ¹æãä¹ãã滎ã å ããŠã枩床ã60â70â
ïŒçºç±åå¿ïŒã®æž©åºŠã«ä¿æãããæ·»å ãå®äºã
ãã°ãã®æ··åç©ã80âã§40åéæ¹æããã12.4
ïœã®çæç©ãç空ïŒ2mmHïœïŒèžæºã§åŸãã
ããNMRã¹ãã¯ãã©ã ã¯åæããŠããã (b) 12.46ïœã®ïœâããããã³ãºã¢ã«ãããã
17.7ïœã®çæç©ïœïŒåã³11.8ïœã®Î²âã¢ããã¯
ããããŒãã90âã«å ç±ããïŒçºç±åå¿ã§ã¬ã¹
ãçºçããïŒã枩床ã90â100âã«ïŒæéä¿æã
ããæ®æž£ãSiO2ã溶åºæ¶²CH2Cl2ïŒCH2Cl2ïŒ
MeOHïŒEt3NïŒ95ïŒïŒïŒ0.5ïŒã§ã¯ãããã°ã©
ãã€ãŒã«ããããçæç©ïŒèç¹185â188âïŒã®
14ïœãåŸãããã IRïŒé±æ²¹åæ£ïŒïŒ1680-1cmãšã¹ãã«åºã®DCïŒ
ïŒïŒã¢ã³ã¢ããŠã ã°ã«ãŒãã®Îœ2350â2700cm  NH+ âCD3SOCD3ïŒïŒÎŽ1.19ïŒïœã3H.
CH3(a)ïŒã1.69ïŒãããŒãã6HãCH2(b)ïŒã2.32ãš
2.40ïŒïœã3HãCH3(c)ïŒã2.8â3.5ïŒïœã6Hã
CH2N(d)ïŒã4.0ïŒïœã2HãCH2(e)ïŒã4.45ïŒïœã
2HãCOOCH2CH2(f)ïŒã5.05ïŒïœã1Hã
ã«âβâã¢ããã¯ããã³é žãšã¹ãã«åã³ïŒâãã
ãªãžããšã¿ããŒã«ã¢ã»ããŒããã次åŒã«ããåå¿
ãããããšã«ãã補é ãããã ãã®åå¿ã¯ãæ®é溶å€ã®äžååšäžãçŽ90â100
âã®æž©åºŠã§æ°æéãè¡ãªãããã ïœâããããã³ãºã¢ã«ããããšÎ²âã¢ããã¯ã
ãããŒããšã¯åžå Žã§å ¥æã§ãããããããã¯å ¬ç¥
æ¹æ³ã§è£œé ããããšãã§ãããïŒâãããªãžããš
ã¿ããŒã«ã¢ã»ãã¢ã»ããŒãã¯ãœãŒãããªãžãã¡ã¿
ããŒã«ãšãžã±ãã³ãšãã¢ãã³ã®ååšäžã§åå¿ããŠ
æå©ã«è£œé ã§ããã äžèšã®äŸã¯æ¬çºæãæŽã«èª¬æãããã®ã§ãã
ãã決ããŠããããå¶éãããã®ã§ã¯ãªãã å®æœäŸ (a) ïŒâãããªãžããšã¿ããŒã«âã¢ã»ãã¢ã»ããŒ
ã ãžã±ãã³ïŒ8.1mlïŒãïŒâãããªãžããšã¿ã
ãŒã«ïŒ9.36mlïŒãšããªãšãã«ã¢ãã³ïŒ0.05mlïŒ
ãšã«æ¹æãä¹ãã滎ã å ããŠã枩床ã60â70â
ïŒçºç±åå¿ïŒã®æž©åºŠã«ä¿æãããæ·»å ãå®äºã
ãã°ãã®æ··åç©ã80âã§40åéæ¹æããã12.4
ïœã®çæç©ãç空ïŒ2mmHïœïŒèžæºã§åŸãã
ããNMRã¹ãã¯ãã©ã ã¯åæããŠããã (b) 12.46ïœã®ïœâããããã³ãºã¢ã«ãããã
17.7ïœã®çæç©ïœïŒåã³11.8ïœã®Î²âã¢ããã¯
ããããŒãã90âã«å ç±ããïŒçºç±åå¿ã§ã¬ã¹
ãçºçããïŒã枩床ã90â100âã«ïŒæéä¿æã
ããæ®æž£ãSiO2ã溶åºæ¶²CH2Cl2ïŒCH2Cl2ïŒ
MeOHïŒEt3NïŒ95ïŒïŒïŒ0.5ïŒã§ã¯ãããã°ã©
ãã€ãŒã«ããããçæç©ïŒèç¹185â188âïŒã®
14ïœãåŸãããã IRïŒé±æ²¹åæ£ïŒïŒ1680-1cmãšã¹ãã«åºã®DCïŒ
ïŒïŒã¢ã³ã¢ããŠã ã°ã«ãŒãã®Îœ2350â2700cm  NH+ âCD3SOCD3ïŒïŒÎŽ1.19ïŒïœã3H.
CH3(a)ïŒã1.69ïŒãããŒãã6HãCH2(b)ïŒã2.32ãš
2.40ïŒïœã3HãCH3(c)ïŒã2.8â3.5ïŒïœã6Hã
CH2N(d)ïŒã4.0ïŒïœã2HãCH2(e)ïŒã4.45ïŒïœã
2HãCOOCH2CH2(f)ïŒã5.05ïŒïœã1Hã
ãåŒãïŒ7.5â8.1ïŒïœã4Hã
ArïŒã9.45ïŒïœã1HãHClïŒã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ã®ååç©åã³ãããã®è¬åŠçã«èªå®¹ã§ããææ©ãŸ
ãã¯ç¡æ©é žã®å¡©ã ïŒ ïœâããããã³ãºã¢ã«ãããããšãã«âβâ
ã¢ããã¯ããã³é žãšã¹ãã«åã³ïŒâãããªãžããš
ã¿ããŒã«ã¢ã»ãã¢ã»ããŒããåå¿ãããããšãç¹
城ãšãããäžè¬åŒïŒ ã®ååç©åã³ãããã®è¬åŠçã«èªå®¹ã§ããææ©ãŸ
ãã¯ç¡æ©é žã®å¡©ã®è£œé æ¹æ³ã ïŒ 90ãã100âã®ç¯å²å ã®æž©åºŠã§ã溶å€ã®äžå
åšäžã§æäœããããšãç¹åŸŽãšãããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ æå¹ç©è³ªãšããŠã®äžè¬åŒïŒ ã®ååç©åã³ãããã®è¬åŠçã«èªå®¹ã§ããææ©ãŸ
ãã¯ç¡æ©é žã®å¡©åã³å°ãªããšãäžçš®ã®äžæŽ»æ§æ äœ
åã³ïŒåã¯å©å€ãå«æããåèè¡ç®¡åçž®æå¶å€ã ïŒ çµå£ãçµç®åã¯çµè žæäžã®ããã®ãç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®è¬å€ã ïŒ éè溶æ§åã³è žæº¶æ§ã«ãã»ã«åã¯é å€ãšããŠ
ã®ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒè¬å€ã ïŒ æå¹ç©è³ªãšããŠã®äžè¬åŒïŒ ã®ååç©åã³ãããã®è¬åŠçã«èªå®¹ã§ããææ©ãŸ
ãã¯ç¡æ©é žã®å¡©åã³å°ãªããšãäžçš®ã®äžæŽ»æ§æ äœ
åã³ïŒåã¯å©å€ãå«æããè³å Ca++ã€ãªã³èç©
é²æ¢å€ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22364/85A IT1201476B (it) | 1985-10-04 | 1985-10-04 | Derivato diidropiridinico,procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono |
| IT22364A/85 | 1985-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62161758A JPS62161758A (ja) | 1987-07-17 |
| JPH0480026B2 true JPH0480026B2 (ja) | 1992-12-17 |
Family
ID=11195258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61234248A Granted JPS62161758A (ja) | 1985-10-04 | 1986-09-30 | ãžãããããªãžã³èªå°äœããã®è£œæ³ããããå«æããåèè¡ç®¡åçž®æå¶å€åã³è³å ã«ã«ã·ãŠã ã€ãªã³èç©åŠšæ¢å€ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4826856A (ja) |
| EP (1) | EP0218996B1 (ja) |
| JP (1) | JPS62161758A (ja) |
| AT (1) | ATE55988T1 (ja) |
| DE (1) | DE3673744D1 (ja) |
| ES (1) | ES2017613B3 (ja) |
| IT (1) | IT1201476B (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT388731B (de) * | 1987-12-15 | 1989-08-25 | Gerot Pharmazeutika | Neue derivate von benzimidazol, ihre herstellung und verwendung |
| US5089502A (en) * | 1989-06-02 | 1992-02-18 | E. R. Squibb & Sons, Inc. | Method for preventing or treating anxiety employing a calcium channel blocker |
| CA2016465A1 (en) * | 1989-06-02 | 1990-12-02 | Zola Phillip Horovitz | Method for preventing or treating anxiety employing a calcium channel blocker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2218644C3 (de) * | 1972-04-18 | 1982-08-19 | Bayer Ag, 5090 Leverkusen | Basische Ester von 1,4-Dihydropyridinen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| US4031104A (en) * | 1972-04-18 | 1977-06-21 | Bayer Aktiengesellschaft | 1,4-Dihydropyridine carboxylic acid esters |
| JPS57175166A (en) * | 1981-04-23 | 1982-10-28 | Banyu Pharmaceut Co Ltd | Carbamoyloxyalkyl-1,4-dihydropyridine derivative and its preparation |
-
1985
- 1985-10-04 IT IT22364/85A patent/IT1201476B/it active
-
1986
- 1986-09-30 JP JP61234248A patent/JPS62161758A/ja active Granted
- 1986-10-01 AT AT86113538T patent/ATE55988T1/de active
- 1986-10-01 DE DE8686113538T patent/DE3673744D1/de not_active Expired - Fee Related
- 1986-10-01 EP EP86113538A patent/EP0218996B1/en not_active Expired - Lifetime
- 1986-10-01 ES ES86113538T patent/ES2017613B3/es not_active Expired - Lifetime
-
1988
- 1988-02-18 US US07/157,487 patent/US4826856A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IT8522364A0 (it) | 1985-10-04 |
| ATE55988T1 (de) | 1990-09-15 |
| US4826856A (en) | 1989-05-02 |
| EP0218996A2 (en) | 1987-04-22 |
| EP0218996B1 (en) | 1990-08-29 |
| DE3673744D1 (de) | 1990-10-04 |
| JPS62161758A (ja) | 1987-07-17 |
| ES2017613B3 (es) | 1991-03-01 |
| IT1201476B (it) | 1989-02-02 |
| EP0218996A3 (en) | 1988-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001523712A (ja) | ïœïœ âïœïœã®ãã³ãŒã³ã¹ã«ãã³ã¢ããé»å®³å€ããã³ãããã®æ²»ççäœ¿çš | |
| SK167698A3 (en) | Polymorphs of donepezil hydrochloride and process for production | |
| US6518288B2 (en) | Amlodipine fumarate | |
| US20040116478A1 (en) | Novel amlodipine camsylate and method for preparing thereof | |
| AU2002243069A1 (en) | Novel amlodipine camsylate and method for preparing thereof | |
| CA2525700C (en) | S-(-)-amlodipine nicotinate and process for the preparation thereof | |
| EA014101B1 (ru) | ÐÐœÑагПМОÑÑ cd80 | |
| JPH0480026B2 (ja) | ||
| CA2433193C (en) | Amide derivative of amlodipine | |
| JPH0529209B2 (ja) | ||
| RU2081869C1 (ru) | ÐÑПОзвПЎМÑе 1,4-ЎОгОЎÑПпОÑОЎОМа О ÑаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ ÐœÐ° ÐžÑ ÐŸÑМПве, ПблаЎаÑÑÐ°Ñ Ð²Ð°Ð·ÐŸÐ°ÐºÑОвМÑÐŒ ЎейÑÑвОеЌ | |
| JPS60116678A (ja) | ïœâãããããŒã«ã¢ãã³èªå°äœãšãŒãã« | |
| EP0146159A1 (en) | Ether of n-propanolamine derivative | |
| US7199247B2 (en) | Amide derivative of amlodipine | |
| JPH0615553B2 (ja) | ãžãããããªãžã³âïŒâãã¹ãã³ã¢ããé žé¡ | |
| JPS6144889A (ja) | ã°ã«ã¿ã«ã€ããèªå°äœããã³ãããå«æããå»è¬çµæç© | |
| JPWO1993005778A1 (ja) | è¡äžè質代è¬æ¹åå€ | |
| JP2003026677A (ja) | ïŒâãã§ãã«âïŒïŒïŒâãžã¢ã¶ãã·ã¯ãïŒïŒïŒïŒïŒïŒœããã³âååç©ããããå«æããå»è¬åããã®äœ¿çšåã³ãã®è£œæ³ | |
| CZ296619B6 (cs) | Modifikace donepezilhydrochloridu, zpusob jejà vÜroby a pouzità | |
| KR20210046115A (ko) | ëìì ì ë첎 ë° ìŽë¥Œ íšì íë ìœí ì¡°ì±ë¬Œ | |
| US4146628A (en) | Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds | |
| JPS58210063A (ja) | æ°èŠãªãžãããããªãžã³é¡ | |
| JP4613496B2 (ja) | äžæŽèæ²»çå€ | |
| DK162442B (da) | 3-(2-(furoyl)-5-(eventuelt substitueret)alkoxy-carbonyl-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridiner og farmaceutisk praeparat indeholdende saadanne forbindelser | |
| JP2003128550A (ja) | éåæ©èœäœäžæ¹åå€ |